Medpace (MEDP) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Medpace (MEDP) is set to announce its Q3 2025 earnings on October 22, with analysts expecting earnings of $3.49 per share and revenue of $640.487 million.
• The company recently reported an EPS of $3.10 for Q2 2025, surpassing the consensus estimate, while revenue rose 14.2% year-over-year.
• CEO August J. Troendle recently sold 48,487 shares of Medpace stock, resulting in a 4.80% decrease in ownership, amidst ongoing insider transactions.

Medpace (NASDAQ:MEDP - Get Free Report) will likely be announcing its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect the company to announce earnings of $3.49 per share and revenue of $640.4870 million for the quarter. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS.Investors may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 23, 2025 at 9:00 AM ET.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter last year, the firm posted $2.75 EPS. The business's quarterly revenue was up 14.2% on a year-over-year basis. On average, analysts expect Medpace to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Medpace Stock Performance

NASDAQ:MEDP opened at $516.93 on Wednesday. The firm's 50-day moving average is $486.83 and its 200-day moving average is $377.81. Medpace has a 52-week low of $250.05 and a 52-week high of $547.15. The company has a market cap of $14.52 billion, a price-to-earnings ratio of 38.43, a PEG ratio of 3.31 and a beta of 1.40.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 48,487 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Susan E. Burwig sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the transaction, the vice president owned 57,500 shares in the company, valued at $27,600,000. The trade was a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medpace

Large investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after buying an additional 37 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Medpace by 41.4% in the second quarter. Tower Research Capital LLC TRC now owns 533 shares of the company's stock valued at $167,000 after buying an additional 156 shares during the period. Florida Financial Advisors LLC bought a new stake in Medpace in the second quarter valued at approximately $233,000. M&T Bank Corp increased its stake in Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after purchasing an additional 31 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Medpace in the second quarter valued at approximately $296,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of analyst reports. Rothschild & Co Redburn cut shares of Medpace from a "buy" rating to a "neutral" rating and upped their target price for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Weiss Ratings reissued a "buy (b-)" rating on shares of Medpace in a research note on Wednesday, October 8th. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Mizuho upped their target price on shares of Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Finally, Zacks Research cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 22nd. Two equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Medpace presently has a consensus rating of "Reduce" and a consensus price target of $424.10.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.